Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2012-05-25 Regulatory Filings
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Abstrals framgångar i EU fortsätter. Orexo får delmålsbetalning på 3,3 MEUR.
Regulatory Filings Classification · 1% confidence The document is a 'Pressmeddelande' (Press Release) from Orexo AB dated May 25, 2012. It announces a milestone payment of 3.3 MEUR received from ProStrakan because the accumulated sales of the drug Abstral reached 65 MEUR. This is a specific announcement regarding a financial event tied to a licensing/sales agreement, not a full periodic financial report (like 10-K or IR), a general earnings release (ER), or a management discussion (MDA). It details a specific financial transaction/update related to product performance and licensing milestones. This fits best under Capital/Financing Update (CAP) as it relates to cash inflow from commercial milestones, or potentially Regulatory Filings (RNS) as a general announcement. Given the specific nature of receiving a milestone payment based on sales thresholds, it is a significant financial update. However, since it is a press release announcing a specific financial trigger event (milestone payment), and not a general capital raise or dividend, it is most closely aligned with an Earnings Release (ER) if it were quarterly, but since it's a specific event, it often falls under general Regulatory Filings (RNS) or sometimes Capital (CAP). Since it is a specific, non-periodic financial achievement announcement, and not a general earnings summary, RNS is the safest general regulatory category, but given the context of financial updates, ER is often used for key financial highlights. Since it is a specific milestone payment announcement, and not a comprehensive earnings report, it is best classified as a general Regulatory Filing (RNS) as it doesn't fit the specific financial codes like DIV, CAP, or ER (which usually covers P&L/Balance Sheet highlights). Given the options, RNS is the most appropriate fallback for a specific, non-periodic financial announcement that isn't a formal report.
2012-05-25 Swedish
Orexo presents new focus and plans for commercial expansion – accelerated development of OX219
Investor Presentation Classification · 1% confidence The document is explicitly titled as a 'Press release' and details strategic updates, product pipeline focus (OX219, OX51), market potential, and management commentary presented at a 'Capital Markets Day'. This type of forward-looking strategic presentation material, especially when released via press release, aligns best with an Investor Presentation (IP) or potentially a general Regulatory Filing (RNS) if it were purely informational. However, since it details strategy, pipeline status, and financial outlook presented to investors, 'Investor Presentation' (IP) is the most fitting category, even though the format is a press release summarizing the event. It is not a formal financial report (10-K, IR) or a transcript (CT). Given the context of presenting future plans and strategy to the investment community, IP is selected over the general RNS fallback.
2012-05-03 English
Orexo presenterar nytt fokus och nya planer för kommersiell expansion – accelererar utvecklingen av OX219
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces strategic focus, commercial expansion plans, and development updates for specific assets (OX219, OX51) during a 'kapitalmarknadsdag' (Capital Markets Day). It details financial projections, market potential, and strategic timelines (e.g., FDA submission Q1 2013, US commercial strategy Q4 2012). This content strongly aligns with an Investor Presentation (IP) or a detailed strategic update, rather than a standard regulatory filing like 10-K or ER. Since it is a detailed presentation of strategy and future outlook given to investors, Investor Presentation (IP) is the most appropriate classification. The final line indicates the presentation materials will be available on the website, which might suggest an RPA, but the core content is the detailed strategic update itself, making IP a better fit than RPA or RNS.
2012-05-03 Swedish
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 1% confidence The document is a 'delårsrapport' (interim report) for Orexo for the period January-March 2012. It contains comprehensive financial statements, including income statements, revenue breakdowns, and detailed management commentary on business performance, R&D projects, and financial position. It is clearly a substantive financial report for a period shorter than a full fiscal year, not an announcement or a summary. Q1 2012
2012-04-27 Swedish
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for Orexo for the first quarter of 2012 (January-March). It contains detailed financial statements, including a consolidated statement of operations, revenue breakdowns, and analysis of costs, earnings, and financial position. It is not an announcement of a report (RPA) because it contains the actual financial data and analysis. It is not a 10-K as it covers only a three-month period. Therefore, it is classified as an Interim/Quarterly Report. Q1 2012
2012-04-27 English
Reminder: Invitation to Capital Markets Day 2012
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Reminder: Invitation to Capital Markets Day 2012" and details the agenda, speakers, time, and venue for an upcoming event where management will present strategy, financial review, and business updates. A Capital Markets Day is an event designed to present detailed information to investors and analysts, similar in purpose to an Investor Presentation (IP) or a detailed segment of an Annual Report/Interim Report presentation, but focused on future strategy and pipeline. Since the document is an invitation and agenda for an event where presentations will be given, it most closely aligns with the Investor Presentation (IP) category, which covers detailed presentations for investors focusing on financials, strategy, and market position. It is not a formal regulatory filing like 10-K or ER, nor is it a transcript of the event itself (CT).
2012-04-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.